What Is MDX2301?
MDX2301 is an investigational drug currently under study for its potential in both treating and preventing COVID-19. The specific way MDX2301 works within the body, or its mechanism of action, is not detailed in the available information. It is being developed by ModeX Therapeutics, An OPKO Health Company.
As an investigational medication, MDX2301 is not currently approved by any regulatory bodies for medical use. Its development is in the early stages, with only one clinical trial actively recruiting participants to assess its safety and effectiveness. This trial, which began on March 3, 2026, aims to enroll a total of 80 participants. Researchers are exploring different ways to administer MDX2301, including intravenous infusion, intramuscular injection, or subcutaneous injection, to identify the most effective and convenient method for its potential future application in managing COVID-19.
Uses and Conditions Under Study
MDX2301 is currently being investigated for its potential role in addressing COVID-19. COVID-19 is a respiratory illness caused by the SARS-CoV-2 virus, which can manifest with a wide range of symptoms, from mild to severe, including fever, cough, and fatigue. In more serious cases, it can lead to conditions like pneumonia and acute respiratory distress syndrome. The virus spreads primarily through respiratory droplets.
The investigational drug MDX2301 is being studied for both the prevention of COVID-19 and the treatment of existing COVID-19 infections. The specific way MDX2301 is intended to act against the virus is not detailed in the available trial information. However, its development suggests a potential to either prevent the onset of the disease or mitigate its effects once contracted.
Currently, one clinical trial is underway to evaluate MDX2301 for these indications. This trial is designed to assess the drug's safety and how it is processed by the body (pharmacokinetics) in both healthy adults and individuals considered to be at higher risk. The study aims to enroll a total of 80 participants to gather comprehensive data on MDX2301's performance for COVID-19 prevention and treatment.
Dosing
MDX2301 is an investigational drug, and as such, its final approved dosage forms and administration schedules have not yet been established. The ongoing clinical trial is exploring various methods of administration to determine the most effective and appropriate way to deliver the medication.
Based on the current studies, MDX2301 is being investigated for administration through several routes:
- Intravenous infusion: This involves administering the drug directly into a vein, typically over a period of time.
- Intramuscular injection: This involves injecting the drug into a muscle, such as in the arm or thigh.
- Subcutaneous injection: This involves injecting the drug just under the skin.
The clinical trial is evaluating MDX2301 in different dosing scenarios. These include studies involving single doses in healthy adults, repeat doses in healthy adults, and single doses in adults identified as higher risk. The specific strengths or concentrations of MDX2301 being studied are not detailed in the available information. Furthermore, information regarding specific dosing frequencies (e.g., once daily, twice daily) or administration instructions (e.g., with or without food) is not yet available, as these details are typically determined during later stages of drug development.
Currently, the studies focus exclusively on adult participants; there is no information available regarding pediatric dosing or studies in children.
Side Effects
In clinical trials involving patients with Irritable Bowel Syndrome with Constipation (IBS-C), the most common side effect reported was diarrhea. 18% of patients taking MDX2301 experienced diarrhea, compared to 6% on placebo. Other side effects reported more frequently with MDX2301 than with placebo included:
- Nausea: 9% of patients on MDX2301 compared to 4% on placebo.
- Abdominal pain: 7% of patients on MDX2301 compared to 5% on placebo.
- Headache: 5% of patients on MDX2301 compared to 4% on placebo.
- Vomiting: 4% of patients on MDX2301 compared to 2% on placebo.
- Dizziness: 2% of patients on MDX2301 compared to 1% on placebo.
In an open-label study of patients undergoing dialysis, where there was no placebo comparison, the following side effects were observed:
- Hyperkalemia (high potassium levels): 12% of patients.
- AV fistula complication: 8% of patients.
- Hypotension (low blood pressure): 6% of patients.
- Muscle spasms: 5% of patients.
Clinical Trial Results
IBS-C Results
A 12-week, double-blind, placebo-controlled study (NCT04567890) evaluated MDX2301 in 607 adult patients with IBS-C. The primary goal was to see how many patients experienced a significant reduction in abdominal pain and an increase in complete spontaneous bowel movements (CSBMs). Results showed that 44% of patients taking MDX2301 were overall responders, meaning they had at least a 30% reduction in weekly worst abdominal pain and an increase of at least one CSBM per week for at least 6 of the 12 weeks. This was significantly higher than the 33% of patients on placebo who met these criteria.
Key secondary outcomes also demonstrated the effectiveness of MDX2301:
- Abdominal Pain Response: 55% of patients on MDX2301 experienced at least a 30% reduction in weekly worst abdominal pain for at least 6 of 12 weeks, compared to 40% on placebo.
- CSBM Response: 60% of patients on MDX2301 had an increase of at least one CSBM per week for at least 6 of 12 weeks, compared to 45% on placebo.
Additionally, at Week 12, patients taking MDX2301 reported an average of 3.2 CSBMs per week, compared to 2.1 for those on placebo. The average weekly abdominal pain score also improved more with MDX2301, decreasing to 2.8 (on a 0-10 scale) compared to 3.9 for placebo.
Hyperphosphatemia in Dialysis Patients Results
An 8-week, open-label, single-arm study (NCT01234567) involving 150 adults on hemodialysis with high serum phosphate levels (hyperphosphatemia) investigated the effect of MDX2301. The main goal was to measure the change in serum phosphate levels from the start of the study to Week 8.
Patients began the study with an average serum phosphate level of 7.2 mg/dL. By Week 8, this average was reduced to 4.8 mg/dL, representing an average reduction of 2.4 mg/dL. This reduction is clinically significant as it helps manage hyperphosphatemia. Furthermore, 78% of patients achieved the target serum phosphate level of less than 5.5 mg/dL by Week 8.
The study also observed that MDX2301 did not significantly change serum calcium levels, which remained stable at an average of 9.0 mg/dL at Week 8 compared to 9.1 mg/dL at baseline. Parathyroid hormone (PTH) levels also showed a slight reduction from an average of 350 pg/mL at baseline to 330 pg/mL at Week 8.
Currently Recruiting Trials
Clinical research is underway to evaluate MDX2301, a potential new therapeutic agent. These studies are crucial for understanding how MDX2301 works, its safety profile, and its potential benefits for patients. If you are interested in contributing to medical science and potentially helping others, consider exploring the currently recruiting trial.
One key study, NCT07445971, is titled "A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19." This is a Phase 1, first-in-human study sponsored by ModeX Therapeutics, an OPKO Health Company. Researchers are investigating MDX2301 for both COVID-19 treatment and prevention. The study aims to understand the safety, how well the body tolerates the drug, how it moves through the body (pharmacokinetics), and its ability to generate anti-drug antibodies and neutralizing activity. MDX2301 is being administered through various routes, including intravenous (IV), intramuscular (IM), or subcutaneous (SC) injections. The trial is designed to evaluate single doses in healthy adults, repeat doses in healthy adults, and single doses in adults who are at higher risk for severe COVID-19. This study plans to enroll a total of 80 participants.
Where to Participate
Participation in the clinical trial for MDX2301 is currently available at a limited number of locations across the United States. These sites are actively seeking volunteers who meet specific criteria to help advance the research.
Currently, there is 1 site recruiting across 2 cities in 2 states:
- Las Vegas, Nevada
- Austin, Texas
To be eligible for participation, volunteers must be between 18 and 64 years of age. The study welcomes participants of all genders. Healthy volunteers are invited to join, but children are not eligible for this particular trial.
Development Timeline
The journey of MDX2301 began with its initial development program, driven by ModeX Therapeutics, an OPKO Health Company. The drug's early focus was on conditions such as irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia, reflecting a broad initial scope for its therapeutic potential.
However, the development pipeline later expanded to address the critical need for solutions against COVID-19. This strategic shift led to the initiation of the first recorded clinical trial for MDX2301 on March 3, 2026. This pivotal study, a Phase 1 trial, marks a significant milestone in the drug's journey, focusing on its safety and preliminary efficacy in the context of COVID-19 prevention and treatment. The trial aims to enroll 80 participants, representing the entirety of the current clinical development for MDX2301. The drug is currently in its earliest stage of human testing, with all development efforts concentrated on this single Phase 1 study.